Andrea Olmos-Ortiz

Dr. Andrea Olmos-Ortiz

Inmunobioquímica, Instituto Nacional de Perinatología, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2015 in Nutrients
Verified
Journal Article
Open access
PDF file
Andrea Olmos-OrtizAndrea Olmos-Ortiz
Andrea Olmos-Ortiz
EAEuclides Avila
Euclides Avila
MDMarta Durand-Carbajal
Marta Durand-Carbajal
Lorenza DiazLorenza Diaz
Lorenza Diaz
Vitamin D has garnered a great deal of attention in recent years due to a global prevalence of vitamin D deficiency associated with an increased risk of a variety of human diseases. Specifically, hypovitaminosis D in pregnant women is highly common and has important implications for the mother and lifelong health of the child, since it has been linked to maternal and child infections, small-for-gestational age, preterm delivery, preeclampsia, gestational diabetes, as well as imprinting on the infant for life chronic diseases. Therefore, factors that regulate vitamin D metabolism are of main importance, especially during pregnancy. The hormonal form and most active metabolite of vitamin D is calcitriol. This hormone mediates its biological effects through a specific nuclear receptor, which is found in many tissues including the placenta. Calcitriol synthesis and degradation depend on the expression and activity of CYP27B1 and CYP24A1 cytochromes, respectively, for which regulation is tissue specific. Among the factors that modify these cytochromes expression and/or activity are calcitriol itself, parathyroid hormone, fibroblast growth factor 23, cytokines, calcium and phosphate. This review provides a current overview on the regulation of vitamin D metabolism, focusing on vitamin D deficiency during gestation and its impact on pregnancy outcomes.

Verified
Journal Article
Open access
PDF file
Andrea Olmos-OrtizAndrea Olmos-Ortiz
Andrea Olmos-Ortiz
MFMaría del Pilar Flores-Espinosa
María del Pilar Flores-Espinosa
IMIsmael Mancilla-Herrera
Ismael Mancilla-Herrera
RVRodrigo Vega-Sánchez
Rodrigo Vega-Sánchez
Lorenza DiazLorenza Diaz
Lorenza Diaz
VZVerónica Zaga-Clavellina
Verónica Zaga-Clavellina
During pregnancy, the placenta, the mother and the fetus exploit several mechanisms in order to avoid fetal rejection and to maintain an immunotolerant environment throughout nine months. During this time, immune cells from the fetal and maternal compartments interact to provide an adequate defense in case of an infection and to promote a tolerogenic milieu for the fetus to develop peacefully. Trophoblasts and decidual cells, together with resident natural killer cells, dendritic cells, Hofbauer cells and other macrophages, among other cell types, contribute to the modulation of the uterine environment to sustain a successful pregnancy. In this review, the authors outlined some of the various roles that the innate immune system plays at the maternal–fetal interface. First, the cell populations that are recruited into gestational tissues and their immune mechanisms were examined. In the second part, the Toll–like receptor (TLR)–dependent immune responses at the maternal–fetal interface was summarized, in terms of their specific cytokine/chemokine/antimicrobial peptide expression profiles throughout pregnancy.

Verified
Journal Article
Open access
PDF file
Andrea Olmos-OrtizAndrea Olmos-Ortiz
Andrea Olmos-Ortiz
MFMaría del Pilar Flores-Espinosa
María del Pilar Flores-Espinosa
Lorenza DiazLorenza Diaz
Lorenza Diaz
PVPilar Velázquez
Pilar Velázquez
CRCarlos Ramírez-Isarraraz
Carlos Ramírez-Isarraraz
VZVerónica Zaga-Clavellina
Verónica Zaga-Clavellina
Gestational Diabetes Mellitus (GDM) is a transitory metabolic condition caused by dysregulation triggered by intolerance to carbohydrates, dysfunction of beta-pancreatic and endothelial cells, and insulin resistance during pregnancy. However, this disease includes not only changes related to metabolic distress but also placental immunoendocrine adaptations, resulting in harmful effects to the mother and fetus. In this review, we focus on the placenta as an immuno-endocrine organ that can recognize and respond to the hyperglycemic environment. It synthesizes diverse chemicals that play a role in inflammation, innate defense, endocrine response, oxidative stress, and angiogenesis, all associated with different perinatal outcomes.

6 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
JGJanice Garcia-Quiroz
Janice Garcia-Quiroz
RGRocío García-Becerra
Rocío García-Becerra
CSClara Leticia Santos-Cuevas
Clara Leticia Santos-Cuevas
GRGerardo Ramírez-Nava
Gerardo Ramírez-Nava
Gabriela Morales-GuadarramaGabriela Morales-Guadarrama
Gabriela Morales-Guadarrama
Lorenza DiazLorenza Diaz
Lorenza Diaz
Calcitriol is a multitarget anticancer hormone; however, its effects on angiogenesis remain contradictory. Herein, we tested whether the antiangiogenic phytochemicals curcumin or resveratrol improved calcitriol antitumorigenic effects in vivo. Triple-negative breast cancer tumoral cells (MBCDF-T) were xenografted in nude mice, maintaining treatments for 3 weeks. Tumor onset, volume and microvessel density were significantly reduced in mice coadministered with calcitriol and curcumin (Cal+Cur). Vessel count was also reduced in mice simultaneously treated with calcitriol and resveratrol (Cal+Rsv). Cal+Cur and Cal+Rsv treatments resulted in less tumor activated endothelium, as demonstrated by decreased tumor uptake of integrin-targeted biosensors in vivo. The renal gene expression of Cyp24a1 and Cyp27b1 suggested increased calcitriol bioactivity in the combined regimens. In vitro, the phytochemicals inhibited both MBCDF-T and endothelial cells proliferation, while potentiated calcitriol’s ability to reduce MBCDF-T cell-growth and endothelial cells migration. Resveratrol induced endothelial cell death, as deduced by increased sub-G1 cells accumulation, explaining the reduced tumor vessel number in resveratrol-treated mice, which further diminished when combined with calcitriol. In conclusion, the concomitant administration of calcitriol with curcumin or resveratrol synergistically promoted anticancer effects in vitro and in vivo in human mammary tumor cells. Whereas the results suggest different mechanisms of action of the phytochemicals when coadministered with calcitriol, the converging biological effect was inhibition of tumor neoangiogenesis.

1 October 2016 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
Andrea Olmos-OrtizAndrea Olmos-Ortiz
Andrea Olmos-Ortiz
JGJanice Garcia-Quiroz
Janice Garcia-Quiroz
RLRebeca López-Marure
Rebeca López-Marure
IGIrma González-Curiel
Irma González-Curiel
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
Lorenza DiazLorenza Diaz
Lorenza Diaz

28 October 2019 in Molecular Human Reproduction
Verified
Journal Article
Open access
PDF file
Andrea Olmos-OrtizAndrea Olmos-Ortiz
Andrea Olmos-Ortiz
MDM Déciga-García
M Déciga-García
EPE Preciado-Martínez
E Preciado-Martínez
LBL Bermejo-Martínez
L Bermejo-Martínez
MFMaría del Pilar Flores-Espinosa
María del Pilar Flores-Espinosa
VZVerónica Zaga-Clavellina
Verónica Zaga-Clavellina
Prolactin (PRL) plays an important role in trophoblast growth, placental angiogenesis and immunomodulation within the feto-maternal interface, where different cell types secrete PRL and express its receptor. During pregnancy, inflammatory signalling is a deleterious event that has been associated with poor fetal outcomes. The placenta is highly responsive to the inflammatory stimulus; however, the actions of PRL in placental immunity and inflammation remain largely unknown. The aim of this study was to evaluate PRL effects on the TLR4/NFkB signalling cascade and associated inflammatory targets in cultured explants from healthy term human placentas. An in utero inflammatory scenario was mimicked using lipopolysaccharides (LPS) from Escherichia coli. PRL significantly reduced LPS-dependent TNF-α, IL-1β and IL-6 secretion and intracellular levels. Mechanistically, PRL prevented LPS-mediated upregulation of TLR-4 expression and NFκB phosphorylation. In conclusion, PRL limited inflammatory responses to LPS in the human placenta, suggesting that this hormone could be critical in inhibiting exacerbated immune responses to infections that could threaten pregnancy outcome. This is the first evidence of a mechanism for anti-inflammatory activity of PRL in the human placenta, acting as a negative regulator of TLR-4/NFkB signaling.